The Liver's Role in Europe's Metabolic Crisis: A Blind Spot No More
As the European Union's Healthier Together initiative nears its conclusion, health experts sound the alarm on a critical gap in the fight against non-communicable diseases (NCDs). The program, designed to tackle major health issues, is accused of overlooking a key player in Europe's metabolic health crisis: the liver.
While the framework covers cardiovascular diseases, diabetes, and mental health, it fails to explicitly address liver disease, despite its strong metabolic connections to obesity and type 2 diabetes. This omission, as specialists argue, is a significant flaw in the EU's NCD strategy.
The Liver: Europe's Metabolic Epidemic Driver
Professor Cyrielle Caussy, a nutrition medicine expert, warns that ignoring liver health is akin to ignoring a central organ driving Europe's metabolic epidemic. "The liver is currently the blind spot," she says. "It sits upstream of Europe's major NCDs, yet it's not on the agenda."
Steatotic Liver Disease (SLD), affecting an estimated four in ten adults worldwide, remains largely invisible in EU strategies. This oversight, experts stress, stems from a deeper misunderstanding of obesity itself.
Obesity: Misunderstood and Misrepresented
"There's a persistent misunderstanding of what obesity is," says Dra Andreea Ciudin Mihai, an endocrinologist and obesity specialist. "It's not just about weight; it's about adipose tissue dysfunction."
This lack of recognition, Mihai argues, leads to stigma and a failure to address the root causes. "As long as obesity is not recognized as a disease, we'll continue to stigmatize it."
GLP-1 Medicines: A Double-Edged Sword
Dra Mihai highlights the availability of "game-changing" drugs for diabetes, fatty liver, and cardiovascular disease. However, access is limited due to a lack of reimbursement, forcing patients to pay out of pocket.
Professor Caussy adds, "Those who need these drugs the most are often those who cannot afford them."
Dr. Kremlin Wickramasinghe, an advisor at the WHO Regional Office for Europe, warns that these medicines should not replace political action on prevention. "I worry that with these drugs, we drop the ball on prevention."
Early Detection: Feasible, Cost-Effective, Yet Underutilized
Experts agree that early detection of advanced liver disease is both feasible and cost-effective. The FIB-4 score, a simple and free test, is now widely recommended. If the score is above 1.3, a more accurate assessment is required, usually through trans-elastography.
"Patients need to know their numbers, their liver stiffness measurement," says Prof. Caussy.
Prevention and Education: A Complex Web
Dr. Gamal Shiha, director of the European Liver Patients' Association (ELPA), emphasizes the need for simple pathways and public awareness. "Not all obese individuals are liver patients. The challenge is educating patients and selecting those who need specialist care."
Dr. Wickramasinghe highlights Europe's prevention gap, which starts long before screening. "We don't talk to 80% of patients about these risk factors, which cause 80% of deaths."
"We need a health system that can address these factors, but there's so much stigma and discrimination that it becomes a controversial issue."
EU Policy: Falling Short
MEP Tomislav Sokol criticizes the EU's slow action on front-of-pack nutrition labeling. "We're not doing enough. In the next Multi-Annual Financial Framework, prevention risks being overlooked."
The EU has the power to implement labeling, marketing, prevention, and pharmaceutical reforms, but these tools remain underutilized. "Most politicians don't see the long-term impact of these measures."
Dr. Wickramasinghe adds, "Any policy seen as negative for industry doesn't get implemented."
Conclusion: A Call for Courage
As Healthier Together enters its final phase, the message is clear: Europe has the evidence and solutions, but political courage is needed to confront commercial pressures and turn the tide on NCDs. The liver's role in metabolic health cannot be overlooked any longer.
What are your thoughts on this critical issue? Is the EU doing enough to address NCDs and liver health? Share your opinions in the comments below!
